We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Infections Defined in Urothelial Bladder Tumors

By LabMedica International staff writers
Posted on 09 Aug 2018
Print article
Image: The Applied Biosystems 7500 real-time PCR System (Photo courtesy of Thermo Fisher Scientific).
Image: The Applied Biosystems 7500 real-time PCR System (Photo courtesy of Thermo Fisher Scientific).
Bladder cancer is estimated to be the 9th most common cancer worldwide and over 90% of bladder tumors are classed as urothelial bladder carcinomas (UBCs), with 75% to 80% presenting at non-muscle-invasive (NMIBC) stages and the remainder presenting at muscle-invasive (MIBC) and metastatic stages.

Recent sequencing studies have done much to unravel the enormous genomic complexity in UBCs; however, this explosion of knowledge has not yet led to the effective application of targeted therapies or a complete understanding of what causes the genomic aberrations that initiate and drive UBC.

Scientists at the University of Birmingham (Birmingham, UK) collected specimens from the primary UBCs of 689 patients recruited to the West Midlands Bladder Cancer Prognosis Programme (BCPP) between 2005 and 2011. The team used extracted DNA to screen for high-risk human papillomaviruses (HPV16 E6, HPV18 E7) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

HPV16 and HPV18 were assayed in a multiplex quantitative polymerase chain reaction (qPCR) using primers and probes for HPV16 E6, HPV18 E7 and GAPDH using an Applied Biosystems 7500 Fast Real-Time PCR System. The team also used qPCR to screen for the BK virus (BKV), JC virus (JCV), or other polyomaviruses (HPyV). RNA from frozen specimens and cell lines was extracted using the RNeasy mini kit. Large T antigen immunohistochemistry was also performed.

The team reported that all 689 UBCs were negative for HPV18. One UBC from a female patient with areas of squamous differentiation was positive for HPV16. The qPCR data indicated variable levels of polyomavirus in 49 UBCs. In the UBCs with low Cts they were able to confirm that 23 were BKV and six were JCV by Sanger sequencing. Polyomavirus large T antigen expression was low but detectable in 70% of the sequencing-confirmed polyomavirus positive samples.

The authors concluded that in United Kingdom patients, the presence of HPV DNA sequences is extremely rare in UBC (<1% of cases). Polyomavirus DNA (predominantly BKV) is more common in UBC, but still only detectable in 7% of cases and in many of these cases at low copy number. Therefore HPV16, HPV18 and HPyV are unlikely to be common causative agents in UBC. The study was published on July 26, 2018, in the journal Scientific Reports.

Related Links:
University of Birmingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.